A Single-Dose, Randomized, Two-Period Crossover Pharmacokinetic Study of 2.0 mg Intranasal Hydromorphone Hydochloride in Healthy Volunteers Using 10 mg/ml and 20 mg/ml Formulations

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/01 → 6/30/02

Funding

  • Intranasal Technology Inc: $59,450.00